vimseltinib (Romvimza)
Jump to navigation
Jump to search
Indications
- treatment of adults with tenosynovial giant cell tumor not candidates for surgery or who have not responded to other treatments
Dosage
30 mg twice weekly, taken at least 72 hours apart
- Capsule: 14 mg, 20 mg, 30 mg
Adverse effects
- fatigue, nausea, diarrhea, headache, rash, serum transaminases
- bone marrow suppressioooooon
Mechanism of action
- blocks colony-stimulating factor 1 receptor (CSF1R antagonist)
- CSF1R is involved in the growth & survival of macrophages
- by inhibiting CSF1R, vimseltinib reduces the number of macrophages in the tumor & shrinks its size.
More general terms
References
- ↑ FDA approves vimseltinib for symptomatic tenosynovial giant cell tumor FDA. Feb 14, 2025 https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-vimseltinib-symptomatic-tenosynovial-giant-cell-tumor